Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last A$0.13 AUD
Change Today 0.00 / 0.00%
Volume 102.0K
As of 9:17 PM 03/31/15 All times are local (Market data is delayed by at least 15 minutes).

pharmaxis ltd (PXS) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/29/14 - A$0.21
52 Week Low
10/30/14 - A$0.04
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PHARMAXIS LTD (PXS)

Related News

No related news articles were found.

pharmaxis ltd (PXS) Related Businessweek News

No Related Businessweek News Found

pharmaxis ltd (PXS) Details

Pharmaxis Ltd, a specialty pharmaceutical company, is engaged in the research, development, and commercialization of human healthcare products for the treatment and management of respiratory and other chronic diseases worldwide. The company’s lead product and product candidates are used for the diagnosis and treatment of chronic respiratory diseases, including asthma, cystic fibrosis, and chronic obstructive pulmonary disease (COPD), including bronchiectasis and chronic bronchitis, and other chronic and acute pulmonary conditions. It offers Aridol lung function test, which is designed to assist physicians in the assessment of asthma by identifying and measuring airway hyperresponsiveness; and Bronchitol, a drug designed to reduce the amount of mucus build-up in the lungs of patients suffering from chronic respiratory conditions. The company’s early product development pipeline includes orbital dry powder inhaler that delivers drug doses to the lungs; Lysyl Oxidase Like 2 (LOXL-2) inhibitors for the treatment of fibrosis; PXS-4728A–novel semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 inhibitor for the treatment of chronic lung inflammation; PXS64/25 targeting lung fibrosis; ASM8 targeting severe asthma; and PXS TPI1100 for the treatment candidate for COPD. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.

90 Employees
Last Reported Date: 02/26/15
Founded in 1998

pharmaxis ltd (PXS) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: A$453.3K
Chief Financial Officer, Company Secretary an...
Total Annual Compensation: A$363.9K
Head of Drug Discovery
Total Annual Compensation: A$240.3K
Medical Director and Member of Disclosure Com...
Total Annual Compensation: A$348.4K
Director of Operations
Total Annual Compensation: A$246.9K
Compensation as of Fiscal Year 2014.

pharmaxis ltd (PXS) Key Developments

Pharmaxis Introduces HLC Baby B and HlC Baby F

Pharmax has launched its new HLC Baby B and HLC Baby F probiotic supplements. The probiotic strains utilised in HLC Baby B and HLC Baby F probiotic formulas were assessed in a recent clinical trial, in which they were found to be safe and effective in decreasing incidence of skin sensitivity in infants. HLC Baby B is designed for breast-fed babies while HLC Baby F is suitable for formula-fed babies. A 2014 placebo-controlled clinical trial conducted by Allen et al. indicated that probiotic supplementation with the HLC Baby B and F strains in babies from birth to six months reduced skin prick reaction by 44% and reduced skin sensitivity by 57%. In addition, a 2010 safety study conducted by Allen et al, found that the usage of these probiotic strains did not increase adverse event incidence, number of visits to the doctor, or mothers' assessment of infant health. Based on the data from these trials, the authors concluded that usage of the probiotic formula was safe during early infancy.

Pharmaxis Ltd. Announces Consolidated Earnings Results for the Half Year Ended Dec. 31, 2014

Pharmaxis Ltd. announced consolidated earnings results for the half year ended Dec. 31, 2014. For the period, the company reported revenue from continuing operations of AUD 12,538,000 compared to AUD 5,382,000 a year ago. Loss before income tax was AUD 6,477,000 compared to AUD 20,637,000 a year ago. Loss was AUD 6,572,000 or 0.02 cents per basic and diluted share compared to AUD 20,698,000 or 6.7 cents per basic and diluted share a year ago. Net cash outflow from operating activities was AUD 13,456,000 compared to AUD 12,603,000 a year ago. Payments for plant and equipment amounted to AUD 88,000 compared to AUD 56,000 a year ago. Payments for intangible assets amounted to AUD 19,000 compared to AUD 35,000 a year ago. Adjusted LBITDA was AUD 6,986,000 compared to AUD 13,428,000 a year ago.

Pharmaxis Ltd. Announces Consolidated Cash Flow Results for the Second Quarter and Six Months Ended December 31, 2014

Pharmaxis Ltd. announced consolidated cash flow results for the second quarter and six months ended December 31, 2014. For the quarter, the company reported net operating cash out flows of AUD 4,653,000. Payments for acquisition of physical non-current assets were AUD 18,000. For the six months, the company reported net operating cash out flows of AUD 13,456,000. Payments for acquisition of physical non-current assets were AUD 88,000.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PXS:AU A$0.13 AUD 0.00

PXS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PXS.
View Industry Companies

Industry Analysis


Industry Average

Valuation PXS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.1x
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMAXIS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at